The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin
- 174 Downloads
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months. All patients received calcium supplementation 1,000 mg and vitamin D 400 IU daily. Bone mineral density (BMD) of the lumbar spine, femoral neck, and trochanter was measured annually using dual-energy X-ray absorptiometry. Bone metabolism measurements included urinary deoxypyridinoline (DPD), serum bone alkaline phosphatase (BAP), and serum osteocalcin (OC).
Over 2 years, the lumbar spine (4.34%, P <0.001), femoral neck (2.52%, P <0.05), and trochanteric (1.29%, P <0.05) BMD in the alendronate group increased significantly. The sCT treatment increased lumbar spine BMD (1.75%, P <0.05), whereas a significant bone loss occurred at the femoral neck at month 24 (−3.76%, P <0.01). A nonsignificant decrease in the trochanteric region was observed in the sCT group (−0.81%). The difference between the groups with respect to the femoral neck and trochanteric BMD was statistically significant ( P <0.001and P <0.05, respectively). The decreases in urinary DPD (−21.87%, P <0.001), serum BAP (−10.60%, P <0.01), and OC (−19.59%, P <0.05) values were statistically significant in the alendronate group, whereas nonsignificant decreases were observed in the sCT group (−5.77%, −1.96%, and −4.31%, respectively). A significant difference was found in the DPD and BAP levels between the two treatment groups in favor of the alendronate group at all time points ( P =0.001 and P <0.05, respectively).
The results of this study demonstrated that alendronate treatment produced significantly greater increases in the femoral neck BMD and greater decreases in bone turnover than intranasal sCT in RA patients receiving low dose glucocorticoids.
KeywordsGlucocorticoids Osteoporosis Rheumatoid arthritis
- 2.DequekerJ, Maenaut K, Verwilghen J, Westhowens R (1995) Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 12:S1–6Google Scholar
- 3.Suzuki Y, Mizushima Y (1997) Osteoporosis in rheumatoid arthritis. Osteoporos Int 7 [Suppl 3]:S217–222Google Scholar
- 4.Celiker R, Gokce-Kutsal Y, Cindas A, Ariyurek M, Renda N, Koray Z, Basgoze O (1995) Osteoporosis in rheumatoid arthritis: effect of disease activity. Clin Rheumatol 14:429–433Google Scholar
- 5.Laan RFJM, van Riel PLCM, van de Putte LBA (1992) Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis 51:826–832Google Scholar
- 7.Kroger H, Honkanen R, Saarikoski S, Alhave E (1994) Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study. Ann Rheum Dis 53:18–23Google Scholar
- 9.Cortet B, Guyot MH, Solau E, Pigny P, Dumoulin F, Flipo RM (2000) Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol 18:683–690Google Scholar
- 11.Deodhar AA, Woolf AD (1996) Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 35:309–322Google Scholar
- 12.Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1995) Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 22:1055–1059Google Scholar
- 17.Cooper C, Coupland C, Mitchell M (1995) Rheumatoid arthritis, corticosteroid therapy, and hip fractures Ann Rheum Dis 54:49–52Google Scholar
- 18.Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S (2003) Bone resorption and inflammatory inhibition of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 30:474–479Google Scholar
- 20.>Geusens P, Dequeker J, Vanhoof J, Stalmans R, Boonen S, Joly J, et al (1998) Cyclical editronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised, placebo controlled study. Ann Rheum Dis 57:724–727Google Scholar
- 22.Eggelmeijer F, Papapoulos SE, vanPaessen H, Dijkmans BEC, Valkema R, Westedt ML (1996) Increased bone mass with pamidronate treatment in rheumatoid arthritis. Arthrits Rheum 39:396–402Google Scholar
- 25.Sileghem A, Geusens P, Dequeker J (1992) Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. Ann Rheum Dis 51:761–764Google Scholar
- 28.Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include 28-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedGoogle Scholar
- 29.Kirwan JR, Reeback JS (1986) Stanford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 25:206–209Google Scholar
- 30.Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18:919–924Google Scholar
- 34.Kotaniemi A, Piirainen H, Paimela L, Leirisalo-Repo M, Uoti-Reilama K, Lahdentausta P, et al (1996) Is continuous intranasal salmon calitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J Rheumatol 23:1875–1879Google Scholar
- 35.Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, et al (2000) Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD001983Google Scholar
- 36.Takahashi M, Kushida H, Hoshino H, Ohishi T, Inoue T (1997) Evaluation of bone turnover in postmenopausal, vertebral fracture, and hip fracture using biochemical markers for bone formation and resorption. J Endocrinol Invest 20:112–117Google Scholar
- 37.Seriolo B, Ferretti V, Sulli A, Caratto E, Fasciolo D, Cutolo M (2002) Serum osteocalcin levels in premenopausal rheumatoid arthritis patients. Ann N Y Acad Sci 966:502–507Google Scholar
- 38.Hall GM, Spector TD, Delmas PD (1995) Markers of bone metabolism in postmenopausal women with rheumatoid arthritis: effects of corticosteroids and hormone replacement therapy. Arthritis Rheum 38:902–906Google Scholar